Can a simple score shorten blood thinner use after a heart attack?

NCT ID NCT06216821

Recruiting now Disease control Sponsor: Shenyang Northern Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether a risk score (OPT-CAD) can safely guide how long heart attack patients need to take two blood thinners after getting a stent. About 3,490 participants will either follow standard 12-month dual therapy or have their therapy reduced to one blood thinner earlier (1 month for low-risk, 3 months for higher-risk). The goal is to see if this personalized approach lowers the combined risk of death, heart attack, stroke, stent clots, and major bleeding.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dual antiplatelet therapy (aspirin and a P2Y12 inhibitor) with de-escalation to a single P2Y12 inhibitor
What this could lead to: If successful, this could provide a personalized approach to shorten the time patients need to take two blood thinners after a heart attack, reducing bleeding risk while still preventing clots.
What could go wrong: This is a single-country, open-label trial, so results may not apply globally. The risk score is new and may not accurately predict outcomes for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE CORONARY SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute coronary syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE CORONARY SYNDROME

Contacts and locations

Locations

General Hospital of Northern Theater Command
RECRUITING

Shenyang, Liaoning, 110016, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.